Intellectual
Property
PG490 Patents
The following tables
cover granted patents in later phases of research or early development:
|
Law Firm/
|
Title |
Country |
Filing date Serial No. |
Status |
Date grantd/ Pat No. |
|
Perkins & |
immuno-suppressive
compounds and methods |
US |
03/01/96
|
Granted |
09/02/97 |
|
Perkins & |
immuno-suppressive
compounds and methods |
US |
09/01/98 (int’l) |
Granted |
10/05/99 |
|
Perkins & |
immuno-suppressive
compounds and methods |
AU |
02/28/97* (int’l)
|
Granted |
02/17/00 |
|
Perkins & |
immuno-suppressive
compounds and methods |
SG |
02/28/97* (int’l) 9804666-7 |
Granted |
11/16/99 |
PG490 Prodrugs
|
Law Firm/
|
Title |
Country |
Filing date Serial No. |
Status |
Date grantd/ Pat No. |
|
Perkins & Coie
|
triptolide prodrugs
having high aqueous solubility |
US |
09/02/99 |
Granted |
11/21/00 |
|
Perkins & Coie |
triptolide prodrugs
having high aqueous solubility |
SG |
09/02/99† 2001010883 |
Allowed: Grant fee due Sept. 2006 |
|
Research agents
The following table covers patents granted on
agents in the early research phase:
|
Law Firm/
|
Title |
Country |
Filing date Serial No. |
Status |
Date grantd/ Pat No. |
|
Perkins & |
immunotherapy
composition and method |
US |
06/02/94 08/252,953 |
Granted |
12/01/98 |
|
Perkins & |
mammalian dna
topoisomerase II inhibitor and method |
us |
03/18/93 08/032,867 |
Granted |
06/20/95 |
|
Perkins & |
mammalian dna
topoisomerase II inhibitor and method |
us |
06/05/95 08/471,749 |
Granted |
06/17/97 |
|
Perkins & |
tripterinin compound
and method |
us |
03/10/93 08/031,288 |
Granted |
11/21/95 |
|
Perkins & |
method for
suppressing xenograft rejection |
us |
06/07/95 08/484,782 |
Granted |
06/02/98 |
|
Perkins & |
immuno-suppressant
diterpene compound |
us |
01/19/95 08/375,362 |
Granted |
07/15/97 |
|
Perkins & |
antifungal compounds
from pseudomonas viridiflava |
us |
11/26/97 08/978,788 |
Granted |
08/15/00 |
PG490 in Combination
The following table covers patent applications
that are under license:
|
Law Firm/ |
Title |
Country |
Filing date |
Serial No. |
Status |
|
Bozicevic, Field & Francis |
Uses of Diterpenoid Triepoxides As an
Anti-Proliferative Agent |
US |
8/30/1999 |
09/385,917 |
ISSUED as U.S. 6,294,546 |
|
Bozicevic, Field & Francis |
Uses of Diterpenoid Triepoxides As an
Anti-Proliferative Agent |
US |
6/19/2001 |
09/884,898 |
Allowed – Issue Fee Paid |
|
Law Firm/ |
Title |
Country |
Filing date |
Serial No. |
Status |
|
Bozicevic, Field & Francis |
combined therapy of
diterpenoid triepoxides and trail for synergistic killing of tumor |
US |
02/15/00 |
09/505,250 |
ISSUED as U.S. |
Intellectual Property In-License
In February 2003, Pharmagenesis, Inc. obtained an exclusive license to these combination inventions to develop, manufacture, and sell in the field of use of therapeutics. These inventions are useful for treatment of cancer with a combination of Triptolide (PG490) or a related molecule, and an anti-cancer drug, such as, Camptosar® or Navelbine®, and the diagnosis of tumors that are susceptible to such combination.
Trademarks
In the U.S.,
Pharmagenesis, Inc. has obtained trademark on the name “Pharmagenesis”.
Pharmagenesis, Inc. also is seeking this trademark in the EU. The name
“Pharmagenesis” and the design shown below have also been registered as
trademarks in China.
